Actuate announces preclinical synergy for elraglusib with RAS inhibitors
Actuate Therapeutics said it announced new preclinical data showing synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.